Top in hem/onc: Impact of inflation on medical practices; FDA withdrawal of lymphoma drug
In the latest installment of Residency to Retirement, experts discussed how physicians can safeguard their assets from inflation. It was the top story in hematology/oncology last week.
The second top story was about the FDA withdrawing its approval of Ukoniq (umbralisib, TG Therapeutics) for lymphoma indications. The decision was based on results of a randomized phase 3 trial that demonstrated a potential increased risk for death in those who received the agent.
Read these and more top stories in hematology/oncology below:
How inflation may affect your practice and finances, steps to take now
In the last 12 months, there has been a plethora of factors that have inched up the consumer price index, the key gauge the Federal Reserve uses as a barometer of inflation. Read more.
Safety concerns prompt FDA to withdraw Ukoniq approval for two types of lymphoma
The FDA has withdrawn approval of umbralisib for marginal zone lymphoma and follicular lymphoma due to safety concerns, according to an updated drug safety communication. Read more.
Women at greater risk for more severe adverse events from cancer treatments
Women demonstrated a 34% increased risk for severe adverse events from any cancer treatment compared with men, according to a study published in Journal of Clinical Oncology. Read more.
FDA approves Opdivo-based combinations for esophageal squamous cell carcinoma
The FDA has approved Opdivo (nivolumab, Bristol Myers Squibb) plus fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus Yervoy (ipilimumab, Bristol Myers Squibb) as first-line treatments for adults with unresectable advanced or metastatic esophageal squamous cell carcinoma. Read more.
FDA approves Kymriah for advanced follicular lymphoma
The FDA granted accelerated approval to Kymriah (tisagenlecleucel, Novartis) for treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Read more.